| |
Antibodies are a crucial reagent in R&D, diagnostics, & therapeutics. Download the eBook to learn how you can apply custom antibodies in your work. 
|
|
Today's Big NewsDec 14, 2022 |
| By Nick Paul Taylor The unraveling of Exicure continues apace. Weeks after the biotech raised the specter of bankruptcy, AbbVie and Ipsen have terminated their hair loss disorder and rare neurodegenerative disease collaborations with the company. |
|
|
|
By Fraiser Kansteiner Senator Elizabeth Warren of Massachusetts and Vermont senator-elect Peter Welch blasted Pfizer’s purported Comirnaty pricing scheme—which could see the company charge between $110 and $130 per vaccine dose on the private market—as “pure and deadly greed.” |
By Robert King A new analysis found over the past two years the COVID-19 vaccine has prevented more than 18 million additional hospitalizations and 3 million additional deaths. |
By Andrea Park Nearly four years after appointing its first CEO, Activ Surgical has found a new leader to head up the surgical software startup. |
|
If the clinical supply chain is poorly managed, sponsors can struggle to cope with the complexities, causing issues. This playbook covers keys to identifying the need to implement an eClinical Supply Chain Management platform. Download now. 
|
|
By Nick Paul Taylor Kymera Therapeutics has generated the first early clinical evidence that its targeted protein degradation technology works in immune-inflammatory diseases. In a small phase 1 trial, Kymera linked the IRAK4 candidate to improvements in symptoms, encouraging its partner Sanofi to take the program forward. |
By Max Bayer FDA advisers said the risks of Cytokinetics' heart failure med outweigh the benefits, pouring cold water on the drug's approval prospects as it awaits a definitive decision from the agency. The company attempted to elevate data showing that the med was particularly useful in the sickest patients. |
By Heather Landi Maternal and infant death rates already were significantly higher in states with abortion bans or restrictions, and women had less access to pregnancy care, according to a new analysis released today. |
By Kevin Dunleavy A federal court in Delaware has not only rejected Vanda’s claim of patent infringement against generic drugmakers Teva Pharmaceuticals and Apotex, it has ruled that four of Vanda’s patent claims are invalid. With generic competition looming, the prospects for Washington, D.C.-based Vanda are dim. |
By Andrea Park Hot on the heels of the U.S. launch of its recharge-free neurostimulation implant to treat incontinence, Axonics is bringing yet another of its sacral neuromodulation devices to our neighbors to the north. |
By Paige Minemyer Bright Health's financial woes continue, and the company is now at risk of being pulled from the New York Stock Exchange. |
By Conor Hale With the goal of building a unified virtual reality platform to aid in treatments for mental and behavioral health, BehaVR and OxfordVR have joined forces—with a transatlantic transaction that’s raised an additional $13 million to boot. |
By Kevin Dunleavy In a licensing agreement with generics drugmaker Eva Pharma of Egypt, Eli Lilly will deliver active pharmaceutical ingredient at a reduced cost for its human and analogue insulin. Lilly also will provide a “pro-bono transfer” of the technology needed to formulate, fill and finish vials and cartridges. The companies plan to provide insulin for 1 million annually by 2030. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we discuss the latest from the Clinical Trials on Alzheimer’s Disease conference. Plus, we cover the week's news including an investigation into Neuralink, Google’s DeepMind and why things aren't working out for PI3Ks. |
|
|---|
|
|
|
Wednesday, January 25, 2023 | 11am ET / 8am PT This webinar, presented by AmerisourceBergen, will deliver insights to manufacturers and payers covering the need for education and best practices for increasing biosimilar adoption, current product landscape and upcoming product launches, and more. Register now. 
|
|
Video Revolutionize your monoclonal antibody (mAb) manufacturing with expert insights. Sponsored by: Gibco |
Whitepaper Learn how to develop a high-performing supply chain for GMP-manufactured chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific. Sponsored by: Thermo Fisher Scientific |
Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
Executive Summary Strategies to help scale-up for commercial manufacturing are critical to getting cell and gene therapies to patients as more advanced therapies reach late-stage clinical studies and regulatory decisions. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| |
|
